Academic Editors
The following people constitute the Editorial Board of Academic Editors for PeerJ. These active academics are the Editors who seek peer reviewers, evaluate their responses, and make editorial decisions on each submission to the journal. Learn more about becoming an Editor.
Matthias Dehmer
Professor of Bioinformatics and Systems Biology. Head of the Insititute for Bioinformatics and Translational Research at UMIT, Hall in Tyrol, Austria.
Kathleen A Kelly
Kathleen Kelly is a Professor who joined the Department of Pathlogy and Lab Medicine in 1999. Dr. Kelly earned her B.S. in Medical Technology and PhD in Immunology at the Ohio State University in Columbus, Ohio. She was a postdoctoral fellow at Washington University in St. Louis, where she worked on the role of T cell subsets in germinal center formation. She then served as a junior faculty member in the Department of Microbiology and Immunology at the University of Arkansas for Medical Sciences. She focused on mucosal immunology and concentrated her studies on immune responses in the reproductive tract.
Dr. Kelly is actively involved in graduate, undergraduate and medical student education. She is a recipient of the Young Scientist Award and past chair of the Immunology Division for the American Society of Microbiology.
Monika Stoll
Professor of Genetic Epidemiology at the Medical Faculty and Director of the Leibniz-Institute for Arteriosclerosis Research at the University of Muenster, Germany. Former Associate Editor of Physiological Genomics, Academic Editor of PLoS ONE. Main research interests: Genetics of complex disease traits, in particular cardiovascular and inflammatory diseases; comparative genomics, evolutionary medicine.
MK Balasubramanian
Principal Investigator and Deputy Director of Temasek Life Sciences Laboratory, Singapore. Member of the editorial boards of Cytoskeleton, eLife, and Faculty of 1000. Winner of the National Science Medal Singapore.
Ulrika Rova
Besides current research activities in pre-treatment and biochemical conversion of lignocellulose Rova has a background in recombinant protein expression, protein crystallization, biochemical characterization of catalytical properties of enzymes.
Ronald G. Crystal
Professor and Chairman, Department of Genetic Medicine, and Bruce Webster Professor of Internal Medicine, at Weill Cornell Medical College. Director of the Belfer Gene Therapy Core Facility. Attending Physician at the Weill Cornell-New York Presbyterian Hospital. Previously, Chief of Pulmonary Branch, NHLBI, NIH.
Elizabeth S. Dennis
CSIRO Fellow. Distinguished professor, University of technology, Sydney, Past Chairman of the Multinational Arabidopsis Genome Project. Past President of the Australian Society of Biochemistry and Molecular Biology, winner Prime Minister's prize for Science.
Anthony A. Grace
Distinguished Professor of Neuroscience; Professor of Psychiatry and Psychology at the University of Pittsburgh. Involved in translational research related to the dopamine system and psychiatric disorders. Past council member of ACNP, NARSAD Distinguished Investigator, Paul Janseen Schizophrenia Research Award, Efron Award, NIMH MERIT Award, Lilly Basic Scientist Award, Elected Fellow of AAAS.
Florian Lang
Professor of Physiology and Head of the Department for Physiology I in Tübingen, Member of the German Academy of Natural Sciences Leopoldina. Former President of the Geman Physiological Society and the Germany Society of Nephrology.
Dominique Lison
Professor of Toxicology and Occupational Medicine at the Catholic University of Louvain and Director of the Louvain Centre of Toxicology and Applied Pharmacology in Brussels, Belgium.
Lorraine O'Driscoll
Lorraine O'Driscoll (BSc(Hons, Pharm), MSc(Res, Clin Pharm), MA(Ed), PhD(Biotech), FTCD) Lorraine holds a BSc(Hons),pharmacology; MSc(Res), clinical pharmacology; MA, education; PhD, biotechnology. In 2012, she was elected to Fellowship in TCD. Following her PhD, Lorraine undertook biotechnology/biomedical research for US and EU industry (including Berlex; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academia. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and University of Miami. Prior to joining TCD in 2008, Lorraine most recently held the position of Senior Research Programme Leader and Lecturer in School of Biotechnology, DCU.
Her research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer.
She has been a P.I. on 5 cancer clinical trials with ICORG. She is TCD's Principal Investigator on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported Breast-PREDICT; and P.I. and Chair, H2020-supported European Network Cooperation in Science and Technology focussed on Exosomes & Microvesicles in Health & Disease which brings together researchers from around the world, in academia and industry.